公司資料
Arbutus 股價、新聞與催化劑
- 股票代碼:
- ABUS
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- Canada
股票表現
4.71 USD (+0.86%)
收盤價
最後更新: 2026年8月17日
842M USD
市值
股價為何變動
As of Aug 17, 2026, ABUS closed up 0.86% at $4.71. No new same-company headline was identified in the current news window.
公司概覽
Hepatitis B Therapeutics
Arbutus Biopharma develops therapies intended to achieve a functional cure for chronic hepatitis B. Its current clinical strategy centers on suppressing viral antigen production with RNA interference.
Imdusiran
Imdusiran is an RNA interference therapeutic that reduces production of hepatitis B viral proteins, including surface antigen. Clinical studies have evaluated it alone and with immune-modulating agents to seek durable off-treatment control.
Phase 2b Strategy
Arbutus has aligned with the FDA on the design and safety parameters of a proposed Phase 2b study of imdusiran. The company is incorporating that feedback into the final clinical protocol.
LNP Intellectual Property
Arbutus retains economic interests in lipid nanoparticle intellectual property through Genevant and related licensing, settlement, and patent-enforcement activities. These rights are separate from its internal hepatitis B development program.
未來催化劑
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。